JP2022506110A5 - - Google Patents

Info

Publication number
JP2022506110A5
JP2022506110A5 JP2021523278A JP2021523278A JP2022506110A5 JP 2022506110 A5 JP2022506110 A5 JP 2022506110A5 JP 2021523278 A JP2021523278 A JP 2021523278A JP 2021523278 A JP2021523278 A JP 2021523278A JP 2022506110 A5 JP2022506110 A5 JP 2022506110A5
Authority
JP
Japan
Prior art keywords
formula
pharmaceutically acceptable
solvate
hydrate
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021523278A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506110A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/058896 external-priority patent/WO2020092592A1/en
Publication of JP2022506110A publication Critical patent/JP2022506110A/ja
Publication of JP2022506110A5 publication Critical patent/JP2022506110A5/ja
Priority to JP2024185222A priority Critical patent/JP2025011310A/ja
Pending legal-status Critical Current

Links

JP2021523278A 2018-10-30 2019-10-30 治療用化合物および組成物 Pending JP2022506110A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024185222A JP2025011310A (ja) 2018-10-30 2024-10-21 治療用化合物および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752503P 2018-10-30 2018-10-30
US62/752,503 2018-10-30
PCT/US2019/058896 WO2020092592A1 (en) 2018-10-30 2019-10-30 Therapeutic compounds and compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024185222A Division JP2025011310A (ja) 2018-10-30 2024-10-21 治療用化合物および組成物

Publications (2)

Publication Number Publication Date
JP2022506110A JP2022506110A (ja) 2022-01-17
JP2022506110A5 true JP2022506110A5 (cg-RX-API-DMAC10.html) 2022-10-28

Family

ID=70464752

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021523278A Pending JP2022506110A (ja) 2018-10-30 2019-10-30 治療用化合物および組成物
JP2024185222A Pending JP2025011310A (ja) 2018-10-30 2024-10-21 治療用化合物および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024185222A Pending JP2025011310A (ja) 2018-10-30 2024-10-21 治療用化合物および組成物

Country Status (10)

Country Link
US (1) US20210261524A1 (cg-RX-API-DMAC10.html)
EP (1) EP3873444A4 (cg-RX-API-DMAC10.html)
JP (2) JP2022506110A (cg-RX-API-DMAC10.html)
KR (1) KR20210087467A (cg-RX-API-DMAC10.html)
CN (1) CN112996495A (cg-RX-API-DMAC10.html)
AU (1) AU2019373237A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021008345A2 (cg-RX-API-DMAC10.html)
CA (1) CA3117470A1 (cg-RX-API-DMAC10.html)
IL (1) IL282766A (cg-RX-API-DMAC10.html)
WO (1) WO2020092592A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499532B2 (en) 2014-02-07 2016-11-22 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
WO2019156929A1 (en) 2018-02-07 2019-08-15 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
CA3117549A1 (en) * 2018-10-30 2020-05-07 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
EP4213857A4 (en) * 2020-09-17 2024-11-20 Exithera Pharmaceuticals Inc. THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
CN116782911A (zh) * 2020-09-17 2023-09-19 艾克赛特赫拉制药有限责任公司 治疗性化合物、组合物及其使用方法
TW202346278A (zh) * 2022-03-28 2023-12-01 大陸商四川海思科製藥有限公司 2-氨基吡啶衍生物製備方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802206D0 (sv) * 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
CA2648522A1 (en) * 2005-04-04 2006-10-12 Daiamed, Inc. Substituted azetidinones
JP5385895B2 (ja) * 2007-04-10 2014-01-08 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なチアゾリル化合物
LT2766346T (lt) * 2011-10-14 2017-06-12 Bristol-Myers Squibb Company Pakeistieji tetrahidroizochinolino junginiai, kaip faktoriaus xia inhibitoriai
US9499532B2 (en) * 2014-02-07 2016-11-22 eXIthera Pharmaceuticals Inc. Therapeutic compounds and compositions
US20190315711A1 (en) * 2016-12-23 2019-10-17 Exithera Pharmaceuticals, Inc. Therapeutic compounds and compositions

Similar Documents

Publication Publication Date Title
Gimson et al. Earlier charcoal haemoperfusion in fulminant hepatic failure
JP2022523712A5 (cg-RX-API-DMAC10.html)
JP2022506109A5 (cg-RX-API-DMAC10.html)
Nicolau et al. Myoglobin clearance during continuous veno-venous hemofiltration with or without dialysis
Buchanan Sulphamethoxazole, hypoalbuminaemia, crystalluria, and renal failure
Heney et al. Continuous arteriovenous haemofiltration in the treatment of tumour lysis syndrome
Ponikvar et al. Use of prostacyclin as the only anticoagulant during continuous venovenous hemofiltration
Schmidt et al. Studies on the neurotoxicity of ethambutol and its racemate for the rhesus monkey
Heath et al. Treatment of antidepressant poisoning with resin hemoperfusion
Gaynor Use of modified ultrafiltration after repair of congenital heart defects
RU2021115308A (ru) Терапевтические соединения и композиции
JP2006502231A5 (cg-RX-API-DMAC10.html)
Clar et al. Hemofiltration: determinants of drug loss and concentration
Dorsey Venoarterial bypass in hypothermia
CN102205115B (zh) 乌司他丁作为急腹症引起的中毒性休克的抢救辅助药物的用途
RU2021115313A (ru) Терапевтические соединения и композиция
Caruso et al. Continuous hemodialysis for the management of acute renal failure in the presence of cerebellar hemorrhage: case report
WO1996037205A1 (en) Remedy for endotoxinemia and multiple organ failure induced thereby
Balazs et al. Comparison of effects of quinidine and dihydroquinidine on canine heart
Kawahito et al. Pathophysiology and complications during extracorporeal circulation
Crerar-Gilbert et al. Use of inhaled nitric oxide in pulmonary embolism
Heath et al. Resin hemoperfusion in chloroquine poisoning
Marshall Tricyclic overdose
Fanous et al. Severe anaphylactoid reactions to dextran 70
US3632765A (en) Treatment of shock